3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma
2
Leukemia
2
Recurrence
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, T-Cell
1
Leukemia, Lymphoid
1
Burkitt Lymphoma
1
Interventions
Peripheral Blood Stem Cell Transplantation
5
Cyclophosphamide
5
romidepsin
4
pembrolizumab
4
Lenalidomide
4
Etoposide
4
10-propargyl-10-deazaaminopterin
4
Rituximab
3
fludarabine phosphate
2
fludarabine
2
durvalumab
2
carmustine, poliferprosan 20 drug combination
2
Vincristine
2
Prednisone
2
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
2
Melphalan
2
Gemcitabine
2
Doxorubicin
2
Depsipeptides
2
Cytarabine
2
Carmustine
2
Bendamustine Hydrochloride
2
AFM13
2
veliparib
1
thymoglobulin
1
tenalisib
1
temsirolimus
1
prednylidene
1
mogamulizumab
1
forodesine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Lymphoma, T-Cell
×
forodesine
×
Clear all
NCT00742495
2012-10-24
BCX1777-108
Mundipharma Research Limited
Phase 1/2
Terminated
2 enrolled